联环药业：公司拟以自有及自筹资金5000万元增加联环（安庆）注册资本

Group 1 - The core point of the article is that Lianhuan Pharmaceutical plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing), by 50 million RMB to support its strategic development goals [1] - After the capital increase, the registered capital of Lianhuan (Anqing) will rise from 131.52 million RMB to 181.52 million RMB [1] - The funding will be used for key needs such as product research and development, license acquisition, and production line expansion [1]